Burning Rock deepens cooperation with Illumina to promote development and standardization of NGS-based cancer therapy selection [in China]
Burning Rock and Illumina jointly announced today that they are joining forces to promote the development and standardization of NGS-based cancer therapy selection i...
Burning Rock initiates the first prospective, multi-center pan-cancer early detection study in China
Burning Rock today announces the initiation of its 14,000 patient PREDICT (Pan-CanceR Early DetectIon ProjeCT) study to further develop and validate its pan-cancer e...
Burning Rock Dx Launches Magnis BR to Innovate Total Process Automation for NGS Testing
Exclusively supported by Agilent, this futuristic technology brings NGS testing to more hospitals
Burning Rock announces the completion of the Series C financing of RMB 850 million and strives to build an international leading tumor precision medicine brand
On February 14, 2019, Burning Rock held the signing ceremony and announced the closing of the Series C financing totaling RMB 850 million.
China's first NGS cancer testing kit made by Burning Rock Dx and licensed
On July 23, 2018, National Medical Products Administration (NMPA) vetted and granted a license to Burning Rock Biotech(Guang Zhou) Co., Ltd. for making a creative hi...
Burning Rock Dx Honored with 2018 Guangzhou Hi-tech “Unicorn” and “High-grade, Precision and Advanced” Startup
Burning Rock and other firms were rated as 2018 hi-tech unicorns in Guangzhou. Besides, Burning Rock was also included into the top ten Guangzhou “high-grade, precis...
Burning Rock Dx Certified by the Certification of ISO 13485 Quality Management System
Lately Burning Rock Dx successfully passed certification of the ISO 13485 Quality Management System and received the corresponding certificate for Burning Rock's ent...
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
August 24, 2015—Burning Rock and Illumina, Inc.(NASDAQ: ILMN) today announced they have entered into an agreement whereby Burning Rock will develop advanced clinical...